Table 4.
Dose planned to PTVboost.
| Patient | PTVboost |
|||||||
|---|---|---|---|---|---|---|---|---|
| D99 (EQD2) |
D95 (EQD2) |
Dmax (EQD2) |
V18 |
|||||
| week 0 | week 3 | week 0 | week 3 | week 0 | week 3 | week 0 | week 3 | |
| 1 | 24 | 25 | 26 | 28 | 92 | 85 | 99 | 100 |
| 2 | 18 | 19 | 22 | 21 | 41 | 41 | 93 | 91 |
| 3 | 31 | 13 | 42 | 18 | 87 | 80 | 100 | 91 |
| 4 | 23 | 30 | 28 | 32 | 51 | 48 | 99 | 100 |
| 5 | 5 | 11 | 8 | 13 | 68 | 55 | 63 | 60 |
| 6 | 5 | 7 | 7 | 9 | 55 | 41 | 56 | 51 |
| 7 | 17 | 18 | 17 | 19 | 48 | 59 | 49 | 61 |
| 8 | 4 | 3 | 7 | 6 | 47 | 51 | 72 | 73 |
| 9 | 30 | 28 | 32 | 31 | 75 | 77 | 100 | 100 |
| 10 | 15 | 12 | 17 | 16 | 66 | 66 | 82 | 84 |
Dose in EQD2, except for V18. Abbreviation: PTVboost: boost planning target volume; D99: dose planned to 99% of PTVboost (EQD2); D95: dose planned to 95% of PTVboost (EQD2); Dmax: maximum dose (EQD2); V18: percentage of planning target volume receiving ≥18 Gy (physical dose); week 0: boost plan based on pre-treatment 18F-FDG-PET/CT; week 3: boost plan based on early response monitoring 18F-FDG-PET/CT.